Research director, professor
Proteomics Program, Novo Nordisk Foundation for Protein Research
Our eventual goal is to prevent the development of diseases such as the metabolic syndrome in the first place, by targeted and personalized life style interventions. To this end, the group builds on its longstanding expertise in mass spectrometry to implement an artificial intelligence-guided platform for analyzing the proteomes of patient tissue from low amounts of formalin-fixed, paraffin-embedded samples at high accuracy and sensitivity. Our highly sensitive methods now enable us to simultaneously profile thousands of proteins from just a few cells, allowing us to identify the proteins that are most critical for various diseases. Another area of focus is the interpretation of ‘multi-omics’ data, which is still a challenge. Often, a single ‘omics’ dimension is not sufficient to capture the full complexity of a disease.